Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes



Status:Recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:April 2011
Contact:Mark B. Sulik, Pharm D.
Email:mark@idahomed.com
Phone:208-528-9642

Use our guide to learn which trials are right for you!

Continuous Glucose Monitoring in Subjects With Type 2 Diabetes


The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has
on subjects with type 2 diabetes. It is anticipated that patients using the device will
obtain tighter control of their blood sugars resulting in measureable health benefits and
improved confidence in their ability to manage their diabetes.


Inclusion Criteria:

- Have been diagnosed with type 2 diabetes mellitus

- Have an HgbA1c value ≥ 7% and ≤17%.

- Are on basal insulin, with or without oral agents

- Are not on basal bolus insulin therapy.

- Have had no severe hypoglycemic episodes in the 6 months prior to enrollment in the
study. Severe hypoglycemia will be defined as any hypoglycemia that is both
neurologically impairing and absolutely requires assistance from a third party in the
form of carbohydrates, glucagon shots, or attention from a paramedic or other
healthcare professional.

- Have no known allergy to medical tape or sensors.

- Are capable of and willing to test their blood glucose (BG) on an average of 4
times per day.

- Are willing to not use Acetaminophen while enrolled in the study.

- Are willing not to undergo a MRI procedure while wearing the CGM sensor.

- Are willing and capable of performing self insertions of the device sensor.

- Women of child bearing potential must be willing to use an approved form of birth
control while enrolled in the study.

- Women of child bearing potential must be willing to perform pregnancy tests monthly
while enrolled in the study.

- Can understand and speak English fluently.

Exclusion Criteria

- Have been on pump therapy in the 6 months prior to enrollment in the study.

- Are receiving basal- bolus insulin therapy

- Are taking any medication that is not approved to be taken with insulin.

- Are pregnant or have intentions of becoming pregnant during the duration of the
study.

- Have any skin condition that would inhibit the proper wearing of the CGM sensor
including severe psoriasis, burns, eczema, scarring, excessive tattoos, etc.

- Have a hematocrit ≤30% or ≥55%

- Are currently enrolled in another clinical study (subjects must have ended
participation in other studies at least 30 days prior to enrolling in this study.

- Are employed by any company that manufactures or is developing a CGM device.

- Are deemed incapable of participating in the study by the Primary Investigator for
any reason.
We found this trial at
1
site
?
mi
from
Idaho Falls, ID
Click here to add this to my saved trials